The SARAF-LINAC Project for SARAF-PHASE 2

THPF005International audienceSNRC and CEA collaborate to the upgrade of theSARAF accelerator to 5 mA CW 40 MeV deuteron andproton beams (Phase 2). This paper presents the referencedesign of the SARAF-LINAC Project including a fourvane176 MHz RFQ, a MEBT and a superconducting linacmade of four five-meter cryomodules housing 26superconducting HWR cavities and 20 superconductingsolenoids. The first two identical cryomodules house lowbeta($\beta$opt = 0.091), 280 mm long (flange to flange), 176MHz HWR cavities, the two identical last cryomoduleshouse high-beta ($\beta$opt = 0.181), 410 mm long, 176 MHz,HWR cavities. The beam is focused with superconductingsolenoids located between cavities housing steering coils.A BPM is placed upstream each solenoid

Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics

Introduction: In previous studies carried out in our laboratory, a bile acid (BA) formulation exerted a hypoglycaemic effect in a rat model of type-1 diabetes (T1D). When the antidiabetic drug gliclazide (G) was added to the bile acid, it augmented the hypoglycaemic effect. In a recent study, we designed a new formulation of gliclazide-cholic acid (G-CA), with good structural properties, excipient compatibility and exhibits pseudoplastic-thixotropic characteristics. The aim of this study is to test the slow release and pH-controlled properties of this new formulation. The aim is also to examine the effect of CA on G release kinetics at various pH values and different temperatures. Method: Microencapsulation was carried out using our Buchi-based microencapsulating system developed in our laboratory. Using sodium alginate (SA) polymer, both formulations were prepared: G-SA (control) and G-CA-SA (test) at a constant ratio (1:3:30), respectively. Microcapsules were examined for efficiency, size, release kinetics, stability and swelling studies at pH 1.5, pH 3, pH 7.4 and pH 7.8 and temperatures of 20 and 30 °C. Results: The new formulation is further optimised by the addition of CA. CA reduced microcapsule swelling of the microcapsules at pH 7.8 and pH 3 at 30 °C and pH 3 at 20 °C, and, even though microcapsule size remains similar after CA addition, percent G release was enhanced at high pH values (pH 7.4 and pH 7.8, p < 0.01). Conclusion: The new formulation exhibits colon-targeted delivery and the addition of CA prolonged G release suggesting its suitability for the sustained and targeted delivery of G and CA to the lower intestine